Compare 10X Genomics Inc (TXG) vs Essential Utilities Inc. Common Stock (WTRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Essential Utilities Inc. Common Stock — how do they compare? 10X Genomics Inc trades at $72.37 (market cap $9.53B), while Essential Utilities Inc. Common Stock trades at $39.82 (market cap $11.31B). The key difference: Essential Utilities Inc. Common Stock is the larger of the two by market cap, and Essential Utilities Inc. Common Stock pays a 3.62% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 91 Days and Essential Utilities Inc. Common Stock for 0 Days on average.
| TXG | WTRG | |
|---|---|---|
Market Cap | $9.53B | $11.31B |
Volume | 4,138,224 | 2,459,172 |
Sector | Health | Utilities |
52-Week High | $97.74 | $42.00 |
52-Week Low | $11.83 | $36.25 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $9.05B | $19.82B |
Dividend Yield | — | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG (10x Genomics) trades at $71.79, down 4.52% on the day, amid a bearish technical signal. The company shows improving fundamentals with a significant reduction in net losses (-$43.54M in 2025 vs. -$183M in 2024) and positive operating cash flow of $136.05M. Recent news highlights strong demand for its new Atera spatial biology platform and a patent victory. However, valuation metrics remain elevated with a P/S of 14.86 and EV/EBITDA of 230.71.
The outlook is cautiously optimistic. Analyst consensus is mixed with a $83.30 price target implying 16% upside, but execution on Atera commercialization and sustained margin improvement are critical. Key risks include high valuation, competitive pressures, and reliance on instrument sales growth. The stock offers growth exposure to spatial biology but requires careful risk management.
WTRG trades at $39.29, up 0.36% with neutral technical signals. The stock shows mixed earnings performance with two beats and one miss in recent quarters, while maintaining strong profitability margins (21.6% net income margin). Analyst consensus is bullish with a $44.50 price target, supported by ongoing acquisitions and pending merger developments with American Water.
The stock presents a stable utility investment with moderate growth potential through strategic acquisitions, though near-term earnings volatility and integration risks from the pending merger warrant caution. Current valuation at 20.15 P/E appears reasonable given the company's consistent cash flow generation and defensive sector positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Essential Utilities Inc. Common Stock
Essential Utilities Inc. is a holding company for regulated water, wastewater, and natural gas utilities, operating under the Aqua and Peoples brands. It serves customers across Pennsylvania, Ohio, Texas, Illinois, North Carolina, New Jersey, Indiana, Virginia, and Kentucky.
Read more on WTRG →
